Green biologics: The algal chloroplast as a platform for making biopharmaceuticals.

Henry N Taunt, Laura Stoffels, Saul Purton

Journal: Bioengineered 2019;9(1):48-54

PMID: 28892417

Abstract

Most commercial production of recombinant pharmaceutical proteins involves the use of mammalian cell lines, E. coli or yeast as the expression host. However, recent work has demonstrated the potential of eukaryotic microalgae as platforms for light-driven synthesis of such proteins. Expression in the algal chloroplast is particularly attractive since this organelle contains a minimal genome suitable for rapid engineering using synthetic biology approaches; with transgenes precisely targeted to specific genomic loci and amenable to high-level, regulated and stable expression. Furthermore, proteins can be tightly contained and bio-encapsulated in the chloroplast allowing accumulation of proteins otherwise toxic to the host, and opening up possibilities for low-cost, oral delivery of biologics. In this commentary we illustrate the technology with recent examples of hormones, protein antibiotics and immunotoxins successfully produced in the algal chloroplast, and highlight possible future applications.

Address: a Algenuity, Eden Laboratory , Stewartby , United Kingdom.; b Algal Research Group, Institute of Structural and Molecular Biology , University College London , Gower Street , London , United Kingdom.

DOI: 10.1080/21655979.2017.1377867

Link outs

Free resources

Full Text Sources:

Medical:

https://medlineplus.gov/dietarysupplements.html

Other Literature Sources:

MeSH Terms: Anti-Bacterial Agents, Biological Products, Chlamydomonas reinhardtii, Chlorophyta, Chloroplasts, Dietary Supplements, Gene Expression, Genetic Engineering, Genetic Vectors, Genome, Chloroplast, Human Growth Hormone, Immunotoxins, Microalgae, Recombinant Proteins, Synthetic Biology, Transformation, Genetic, Transgenes